Skip to main content

Year: 2022

Short-term charter agreement extension

AS Tallink Grupp and Corporate Travel Management (North) Ltd on behalf of The Scottish Government have agreed an extension to the short-term time-charter agreement for the vessel Victoria I. The vessel will be used to provide temporary accommodation in Scotland. The charter has been extended for five months from 14 January 2023. Anneli Simm Investor Relations Consultant AS Tallink Grupp Sadama 5 10111 Tallinn, Estonia E-mail Anneli.simm@tallink.ee

Continue reading

Press Release: Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in AfricaPositive Phase II/III study results support acoziborole’s potential in treatment for deadly diseaseGeneva, Kinshasa, Paris – November 30, 2022. The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigational treatment for sleeping sickness, published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea. Dr Victor KandeFormer Neglected Tropical Diseases Expert Advisor at the Ministry of Health of the DRC, principal investigator of...

Continue reading

Falcon Oil & Gas Ltd. – Granting of stock options

Falcon Oil & Gas Ltd.(“Falcon”, “Company”) Granting of stock options 30 November 2022 – Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) announces that on 29 November 2022 it granted incentive stock options (“Options”) to Tom Layman (Non-Executive Director) to purchase 2,500,000 common shares of Falcon at an exercise price of GBP£0.15 (equivalent to CDN$0.24) under the stock option plan approved at Falcon’s annual shareholders meeting held on 14 July 2022. The Options have a vesting schedule allowing for 1/3 of the Options to vest immediately with an additional 1/3 vesting on each subsequent anniversary until the Options are fully vested on 29 November 2024. The Options have an expiry date of 28 November 2027. Following this grant there are 59,750,000 Options outstanding, representing 5.72% of the issued and outstanding common...

Continue reading

Mkango Releases Financial Statements and Management’s Discussion and Analysis for the Period Ending September 30, 2022

LONDON and VANCOUVER, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) — Mkango Resources Ltd (AIM / TSX-V:MKA) (the “Company” or “Mkango”), is pleased to announce that it has released the Financial Statements and Management’s Discussion and Analysis for the period ending September 30, 2022. The reports will be available under the Company’s profile on SEDAR (www.sedar.com) and on the Company’s website (https://mkango.ca/investors/financials/). For further information on Mkango, please contact:Mkango Resources LimitedWilliam DawesChief Executive Officerwill@mkango.caCanada: +1 403 444 5979www.mkango.ca@MkangoResources Alexander LemonPresidentalex@mkango.ca  BlytheRay Financial Public RelationsTim BlytheUK: +44 207 138 3204   SP Angel Corporate Finance LLP Nominated Adviser and Joint BrokerJeff...

Continue reading

Galantas Reports Financial Results for the Quarter Ended September 30, 2022

TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) — Galantas Gold Corporation (TSX-V & AIM: GAL; OTCQX: GALKF) (“Galantas” or the “Company”) is pleased to announce its unaudited financial results for the quarter ended September 30, 2022. Financial Highlights Highlights of the third quarter 2022 results are summarized below. All figures are in Canadian dollars unless otherwise stated.All figures denominated in Canadian Dollars (CDN$) Quarter EndedSeptember 30 Nine Months EndedSeptember 30  2022 2021 2022 2021Revenue $ 0   $ 0   $ 0   $ 0  Cost and expenses of operations $ (86,442 ) $ (74,462 ) $ (200,076 ) $ (181,943 )Loss before the undernoted $ (86,442 ) $ (74,462 ) $ (200,076 ) $ (181,943 )Depreciation $ (196,178 ) $ (89,151 ) $ (475,045 ) $ (248,304 )General administrative expenses  $ (1,179,927 ) $ (914,174 ) $ (3,764,038 ) $ (4,138,326 )Foreign...

Continue reading

Azerion publishes Interim Unaudited Q3 2022 Results

Continued growth and delivery on M&A pipeline Highlights of Q3 2022Revenue of almost EUR 106 million, compared to EUR 84 million in Q3 2021, mainly driven by strong growth in the Platform segment.  Adjusted EBITDA of over EUR 12 million, down by 30% compared to Q3 2021, primarily due to lower contributions from the Premium Games segment, with Q3 2021 positively impacted by the successful launch of the Habbo NFT project, which impacts comparability versus Q3 2022. Completed acquisitions of Madvertise, Vlyby, Takerate and other asset deals, boosting our offerings to advertisers and publishers. Launched the new Habbo app on Android and iOS.  Expanded integration with Google’s demand-side platform, enabling Google’s Audience targeting, unlocking additional volumes to Azerion’s advertising auction platform Improve Digital. In October...

Continue reading

Net asset value of the EfTEN United Property Fund as of 31.10.2022

The net asset value (NAV) of the EfTEN United Property Fund was 10.99 euros as of October 31, 2022, increasing by 0,4% over the month. Since the start of the fund in late June 2021 the total return has been 10,8% and the return on invested capital 12,3%. The fund has 1/3 of it’s capital as uninvested. The behaviour of tenants in the fund’s larger objects has not been affected by the recent business cycle slowdown in the Baltic countries. The former Danske office building in Vilnius (the fund is invested through the EfTEN Real Estate Fund 5) has a vacancy rate at only 2%, and the Menulio 7 office building at 5%. In October and November, two new lease agreements were signed in the Menulio 7 office building, and the lease agreements with two existing tenants were extended. In November the fund increased its position in EfTEN Kinnisvarafond...

Continue reading

Research Report: Drug Delivery Systems Market Size Worth USD 71.75 Billion by 2029

According to Fortune Business Insights, Drug Delivery Systems Market to Hit USD 71.75 Billion by 2029, Gerresheimer AG and Midas Pharma’s Collaboration for New Generation Cartridge-based Auto Injector’s IP Purchase to Incite Development Pune, India, Nov. 30, 2022 (GLOBE NEWSWIRE) — The global drug delivery systems market size is anticipated to hit USD 71.75 billion by 2029 and exhibit a CAGR of 9.0% during the forecast period. The rising prevalence of chronic diseases, coupled with the increasing patients’ inclination towards advanced drug delivery systems are projected to fuel the market’s growth. Fortune Business InsightsTM has presented this information in its research report titled, “Drug Delivery Systems Market, 2022-2029”. The market size stood at USD 34.70 billion in 2021 and USD 39.33 billion in 2022. Additionally, the...

Continue reading

FRO – Third Quarter and Nine Months 2022 Results

FRONTLINE LTD. REPORTS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2022 Frontline Ltd. (the “Company” or “Frontline”), today reported unaudited results for the three and nine months ended September 30, 2022: HighlightsNet income of $154.4 million, or $0.69 per basic and diluted share for the third quarter of 2022. Adjusted net income of $82.9 million, or $0.37 per basic and diluted share for the third quarter of 2022. Intention to declare and pay the cash dividend in respect of the third quarter of 2022 only after the contemplated voluntary exchange offer by Frontline for Euronav shares that was initially announced on July 11, 2022 (the “Tender Offer”) has been completed. This dividend is expected to be in the amount of 80% of adjusted net income for the third quarter of 2022. Reported total operating revenues of $382.2 million...

Continue reading

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected by BioNTech In addition to these programs, BioNTech will receive a global, exclusive license to develop and commercialize Ryvu’s STING agonist portfolio as standalone small molecules Ryvu will receive €40 million from BioNTech, comprised of a €20 million upfront payment and an equity investment of €20 million, as well as research funding. Additionally, Ryvu is eligible to receive R&D and commercial milestone payments in addition to low single-digit royaltiesMAINZ, Germany and KRAKOW, Poland – November 30, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Ryvu Therapeutics S.A. (Warsaw Stock Exchange: RVU, “Ryvu”), a clinical-stage...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.